Safety of rofecoxib in nonsteroidal anti‐inflammatory drugs intolerance

Muñoz‐Bellido, F. J.; Terrón, M.; León, Amparo

doi:10.1034/j.1398-9995.2003.00166.x

Cited by 7 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increasing number of studies suggest that the COX-2-selective antagonists can be safely taken by patients who develop cutaneous reactions caused by nonselective NSAIDs. 3,4,6 However, here we report that the COX-2-selective inhibitor valdecoxib may induce severe allergic skin reactions.…”

Section: Cox-2-selective Inhibitor Valdecoxib Induces Severe Allergicmentioning

confidence: 62%

“…1 It is characterized clinically by acute and recurrent dysphagia to solid food, occasionally leading to food impaction, vomiting, and abdominal pain, as well as typical endoscopic features and histopathologic findings. 1 Previous observations revealing (1) that more than 70% of adult and 80% of pediatric patients with EE have allergic disorders, 2,3 (2) that the pattern of inflammatory cells and cytokine expression in EE 1 is similar to the findings in allergic diseases of the airways 4 or the skin, 5 (3) that the medication effective in asthma also works in EE, 6 and (4) that allergen challenge of the upper airways leads to eosinophilia in the esophagus in a mouse model of EE 7 raise the question of whether EE can be considered an additional manifestation of atopy. This study was designed to investigate whether EE in adults is connected to airway or food allergies.…”

Section: Cox-2-selective Inhibitor Valdecoxib Induces Severe Allergicmentioning

confidence: 95%

“…2,3 NSAIDs exert their analgesic, antipyretic, anti-inflammatory, and antithrombotic effects by inhibiting both COX-1 and COX-2 activities. [4][5][6] However, the primary responsibility for the synthesis of prostanoids involved in acute and chronic inflammatory states has been credited to COX-2, whereas the gastrointestinal adverse effects have been attributed to COX-1 activity. 1,6 The consequent hypothesis that specific inhibition of this enzyme could have therapeutic effects similar to those of other NSAIDs but without causing gastrointestinal side effects led to the development of COX-2-selective antagonists.…”

Section: Cox-2-selective Inhibitor Valdecoxib Induces Severe Allergicmentioning

confidence: 99%

“…7 COX-2-specific inhibitors have an alleged safer profile compared with other nonselective NSAIDs. [4][5][6] However, several adverse events caused by selective COX-2 inhibitors have been described. 8,9 We report here a case of severe hypersensitivity skin reaction caused by valdecoxib.…”

Section: Cox-2-selective Inhibitor Valdecoxib Induces Severe Allergicmentioning

confidence: 99%

See 3 more Smart Citations

COX-2–selective inhibitor valdecoxib induces severe allergic skin reactions

Talhari

Lauceviciute

Enderlein

et al. 2005

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Section: Cox-2-selective Inhibitor Valdecoxib Induces Severe Allergicmentioning

confidence: 62%

Section: Cox-2-selective Inhibitor Valdecoxib Induces Severe Allergicmentioning

confidence: 95%

Section: Cox-2-selective Inhibitor Valdecoxib Induces Severe Allergicmentioning

confidence: 99%

Section: Cox-2-selective Inhibitor Valdecoxib Induces Severe Allergicmentioning

confidence: 99%

See 2 more Smart Citations

COX-2–selective inhibitor valdecoxib induces severe allergic skin reactions

Talhari

Lauceviciute

Enderlein

et al. 2005

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Current awareness: Pharmacoepidemiology and drug safety

2004

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature

et al. 2007

View full text Add to dashboard Cite

Adverse events triggered by non-steroidal antiinXammatory drugs (NSAIDs) are among the most common drug-related intolerance reactions in medicine; they are possibly related to inhibition of cyclooxygenase-1. Coxibs, preferentially inhibiting cyclooxygenase-2, may therefore represent safe alternatives in patients with NSAID intolerance. We reviewed the literature in a systematic and structured manner to identify and evaluate studies on the tolerance of coxibs in patients with NSAID intolerance. We searched MEDLINE (1966MEDLINE ( -2006, the COCHRANE LIBRARY (4th Issue 2006) and EMBASE (1966EMBASE ( -2006 up to December 9, 2006, and analysed all publications included using a predeWned evaluation sheet. Symptoms and severity of adverse events to coxibs were analysed based on all articles comprising such information. Subsequently, the probability for adverse events triggered by coxibs was determined on analyses of double-blind prospective trials only. Among 3,304 patients with NSAID intolerance, 119 adverse events occurred under coxib medication. All adverse events, except two, have been allergic/urticarial in nature; none was lethal, but two were graded as life-threatening (grade 4). The two non-allergic adverse events were described as a grade 1 upper respiratory tract haemorrhage, and a grade 1 gastrointestinal symptom, respectively. In 13 double-blind prospective studies comprising a total of 591 patients with NSAID intolerance, only 13 adverse reactions to coxib provocations were observed. The triggering coxibs were rofecoxib (2/286), celecoxib (6/208), etoricoxib (4/ 56), and valdecoxib (1/41). This review documents the good tolerability of coxibs in patients with NSAID intolerance, for whom access to this class of drugs for short-term treatment of pain and inXammation is advantageous.

show abstract

Safety of rofecoxib in nonsteroidal anti‐inflammatory drugs intolerance

Cited by 7 publications

References 20 publications

COX-2–selective inhibitor valdecoxib induces severe allergic skin reactions

COX-2–selective inhibitor valdecoxib induces severe allergic skin reactions

Current awareness: Pharmacoepidemiology and drug safety

Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature

Contact Info

Product

Resources

About